1. Home
  2. FEMY vs VNRX Comparison

FEMY vs VNRX Comparison

Compare FEMY & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.53

Market Cap

37.2M

Sector

Health Care

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.20

Market Cap

31.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEMY
VNRX
Founded
2004
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.2M
31.9M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
FEMY
VNRX
Price
$0.53
$0.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$6.83
$2.50
AVG Volume (30 Days)
438.0K
1.9M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
8.60
38.00
EPS
N/A
N/A
Revenue
$1,629,108.00
$1,233,511.00
Revenue This Year
$64.02
$60.84
Revenue Next Year
$147.19
$404.89
P/E Ratio
N/A
N/A
Revenue Growth
51.97
59.10
52 Week Low
$0.31
$0.17
52 Week High
$1.76
$0.94

Technical Indicators

Market Signals
Indicator
FEMY
VNRX
Relative Strength Index (RSI) 44.32 38.64
Support Level $0.33 $0.17
Resistance Level $0.57 $0.33
Average True Range (ATR) 0.04 0.02
MACD 0.01 0.00
Stochastic Oscillator 50.25 33.37

Price Performance

Historical Comparison
FEMY
VNRX

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Share on Social Networks: